Depletion of the human Nα-terminal acetyltransferase A induces p53-dependent apoptosis and p53-independent growth inhibition

International Journal of Cancer

Volumn 127, Issue 12, 2010, Pages 2777-2789

  Gromyko, Darina ^a,b,c   Arnesen, Thomas ^a,b,c   Ryningen, Anita ^c   Varhaug, Jan Erik ^b,c   Lillehaug, Johan R ^a  

^a UNIVERSITY OF BERGEN   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Apoptosis; Growth arrest; N terminal acetylation; NAA10; NatA; P53

Indexed keywords

ACYLTRANSFERASE; CYCLIN D1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; NALPHA TERMINAL ACETYLTRANSFERASE A; PROTEIN P27; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL GROWTH; CELL SURVIVAL; CELL TYPE; CONTROLLED STUDY; DNA DAMAGE; DOWN REGULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; RNA INTERFERENCE; THYROID CANCER; THYROID CARCINOMA;

APOPTOSIS; ARYLAMINE N-ACETYLTRANSFERASE; BLOTTING, WESTERN; CARCINOMA; CARCINOMA, PAPILLARY; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HUMANS; IMMUNOENZYME TECHNIQUES; ISOENZYMES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; THYROID NEOPLASMS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77955297697     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25275     Document Type: Article

References (49)

1. Polevoda B, Sherman F,. The diversity of acetylated proteins. Genome Biol 2002; 3: reviews0006.
2. Sterner DE, Berger SL,. Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 2000; 64: 435 -59.
3. Wang C, Fu M, Mani S, Wadler S, Senderowicz AM, Pestell RG,. Histone acetylation and the cell-cycle in cancer. Front Biosci 2001; 6: D610 -29.
4. Hodawadekar SC, Marmorstein R,. Chemistry of acetyl transfer by histone modifying enzymes: structure, mechanism and implications for effector design. Oncogene 2007; 26: 5528 -40.
5. Polevoda B, Arnesen T, Sherman F,. A synopsis of eukaryotic N-alpha-terminal acetyltransferases: nomenclature, subunits and substrates. BMC Proc 2009; 3 (Suppl 6): S2.
6. Arnesen T, van Damme P, Polevoda B, Helsens K, Evjenth R, Colaert N, Varhaug JE, Vandekerckhove J, Lillehaug JR, Sherman F, Gevaert K,. Proteomics analyses reveal the evolutionary conservation and divergence of N-terminal acetyltransferases from yeast and humans. Proc Natl Acad Sci USA 2009; 106: 8157 -62.
7. Starheim KK, Gromyko D, Velde R, Varhaug JE, Arnesen T,. Composition and biological significance of the human N-alpha-terminal acetyltransferases. BMC Proc 2009; 3 (Suppl 6): S3.
8. Line A, Stengrevics A, Slucka Z, Li G, Jankevics E, Rees RC,. Serological identification and expression analysis of gastric cancer-associated genes. Br J Cancer 2002; 86: 1824 -30.
9. Arnesen T, Gromyko D, Horvli O, Fluge O, Lillehaug J, Varhaug JE,. Expression of N-acetyl transferase human and human arrest defective 1 proteins in thyroid neoplasms. Thyroid 2005; 15: 1131 -6.
10. Fluge O, Bruland O, Akslen LA, Varhaug JE, Lillehaug JR,. NATH, a novel gene overexpressed in papillary thyroid carcinomas. Oncogene 2002; 21: 5056 -68.
11. Martin DT, Gendron RL, Jarzembowski JA, Perry A, Collins MH, Pushpanathan C, Miskiewicz E, Castle VP, Paradis H,. Tubedown expression correlates with the differentiation status and aggressiveness of neuroblastic tumors. Clin Cancer Res 2007; 13: 1480 -7.
12. Midorikawa Y, Tsutsumi S, Taniguchi H, Ishii M, Kobune Y, Kodama T, Makuuchi M, Aburatani H,. Identification of genes associated with dedifferentiation of hepatocellular carcinoma with expression profiling analysis. Jpn J Cancer Res 2002; 93: 636 -43.
13. Ren T, Jiang B, Jin G, Li J, Dong B, Zhang J, Meng L, Wu J, Shou C,. Generation of novel monoclonal antibodies and their application for detecting ARD1 expression in colorectal cancer. Cancer Lett 2008; 264: 83 -92.
14. Yu M, Gong J, Ma M, Yang H, Lai J, Wu H, Li L, Tan D,. Immunohistochemical analysis of human arrest-defective-1 expressed in cancers in vivo. Oncol Rep 2009; 21: 909 -15.
15. Yu M, Ma M, Huang C, Yang H, Lai J, Yan S, Li L, Xiang M, Tan D,. Correlation of expression of human arrest-defective-1 (hARD1) protein with breast cancer. Cancer Invest 2009; 27: 978 -83.
16. Arnesen T, Gromyko D, Pendino F, Ryningen A, Varhaug JE, Lillehaug JR,. Induction of apoptosis in human cells by RNAi-mediated knockdown of hARD1 and NATH, components of the protein N-alpha-acetyltransferase complex. Oncogene 2006; 25: 4350 -60.
17. Lim JH, Park JW, Chun YS,. Human arrest defective 1 acetylates and activates beta-catenin, promoting lung cancer cell proliferation. Cancer Res 2006; 66: 10677 -82.
18. Fisher TS, Etages SD, Hayes L, Crimin K, Li B,. Analysis of ARD1 function in hypoxia response using retroviral RNA interference. J Biol Chem 2005; 280: 17749 -57.
19. Arnesen T, Thompson PR, Varhaug JE, Lillehaug JR,. The protein acetyltransferase ARD1: a novel cancer drug target? Curr Cancer Drug Targets 2008; 8: 545 -53.
20. Arnesen T, Anderson D, Baldersheim C, Lanotte M, Varhaug JE, Lillehaug JR,. Identification and characterization of the human ARD1-NATH protein acetyltransferase complex. Biochem J 2005; 386: 433 -43.
21. Chrisanthar R, Knappskog S, Lokkevik E, Anker G, Ostenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, et al. CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. PLoS One 2008; 3: e3062.
22. Leist M, Jaattela M,. Four deaths and a funeral: from caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001; 2: 589 -98.
23. Li M, Lee TW, Mok TS, Warner TD, Yim AP, Chen GG,. Activation of peroxisome proliferator-activated receptor-gamma by troglitazone (TGZ) inhibits human lung cell growth. J Cell Biochem 2005; 96: 760 -74.
24. Li M, Lee TW, Yim AP, Mok TS, Chen GG,. Apoptosis induced by troglitazone is both peroxisome proliferator-activated receptor-gamma-and ERK-dependent in human non-small lung cancer cells. J Cell Physiol 2006; 209: 428 -38.
25. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L,. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004; 56: 185 -229.
26. Ozoren N, El-Deiry WS,. Cell surface death receptor signaling in normal and cancer cells. Semin Cancer Biol 2003; 13: 135 -47.
27. Wang S,. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008; 27: 6207 -15.
28. Starheim KK, Arnesen T, Gromyko D, Ryningen A, Varhaug JE, Lillehaug JR,. Identification of the human N(alpha)-acetyltransferase complex B (hNatB): a complex important for cell-cycle progression. Biochem J 2008; 415: 325 -31.
29. Starheim KK, Gromyko D, Evjenth R, Ryningen A, Varhaug JE, Lillehaug JR, Arnesen T,. Knockdown of human N alpha-terminal acetyltransferase complex C leads to p53-dependent apoptosis and aberrant human Arl8b localization. Mol Cell Biol 2009; 29: 3569 -81.
30. Ametzazurra A, Larrea E, Civeira MP, Prieto J, Aldabe R,. Implication of human N-alpha-acetyltransferase 5 in cellular proliferation and carcinogenesis. Oncogene 2008; 27: 7296 -306.
31. Hou F, Chu CW, Kong X, Yokomori K, Zou H,. The acetyltransferase activity of San stabilizes the mitotic cohesin at the centromeres in a shugoshin-independent manner. J Cell Biol 2007; 177: 587 -97.
32. Pimenta-Marques A, Tostoes R, Marty T, Barbosa V, Lehmann R, Martinho RG,. Differential requirements of a mitotic acetyltransferase in somatic and germ line cells. Dev Biol 2008; 323: 197 -206.
33. Williams BC, Garrett-Engele CM, Li Z, Williams EV, Rosenman ED, Goldberg ML,. Two putative acetyltransferases, san and deco, are required for establishing sister chromatid cohesion in Drosophila. Curr Biol 2003; 13: 2025 -36.
34. Levine AJ,. p53, the cellular gatekeeper for growth and division. Cell 1997; 88: 323 -31.
35. Ljungman M, Lane DP,. Transcription-guarding the genome by sensing DNA damage. Nat Rev Cancer 2004; 4: 727 -37.
36. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, Olivier M,. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007; 28: 622 -9.
37. Polager S, Ginsberg D,. E2F-at the crossroads of life and death. Trends Cell Biol 2008; 18: 528 -35.
38. Chu IM, Hengst L, Slingerland JM,. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat Rev Cancer 2008; 8: 253 -67.
39. Tenjo T, Toyoda M, Okuda J, Watanabe I, Yamamoto T, Tanaka K, Ohtani M, Nohara T, Kawasaki H, Tanigawa N,. Prognostic significance of p27(kip1) protein expression and spontaneous apoptosis in patients with colorectal adenocarcinomas. Oncology 2000; 58: 45 -51.
40. Maddika S, Ande SR, Panigrahi S, Paranjothy T, Weglarczyk K, Zuse A, Eshraghi M, Manda KD, Wiechec E, Los M,. Cell survival, cell death and cell cycle pathways are interconnected: implications for cancer therapy. Drug Resist Updat 2007; 10: 13 -29.
41. Takubo K, Tsuchiya H, Kurimasa A, Arnesen T, Ryoke K, Shiota G,. Involvement of N-acetyltransferase human in the cytotoxic activity of 5-fluorouracil. Anticancer Drugs 2009; 20: 668 -75.
42. Kruse JP, Gu W,. Modes of p53 regulation. Cell 2009; 137: 609 -22.
43. Toledo F, Wahl GM,. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 2006; 6: 909 -23.
44. Olsson A, Manzl C, Strasser A, Villunger A,. How important are post-translational modifications in p53 for selectivity in target-gene transcription and tumour suppression? Cell Death Differ 2007; 14: 1561 -75.
45. Yu J, Zhang L,. The transcriptional targets of p53 in apoptosis control. Biochem Biophys Res Commun 2005; 331: 851 -8.
46. Geissenhoner A, Weise C, Ehrenhofer-Murray AE,. Dependence of ORC silencing function on NatA-mediated Nalpha acetylation in Saccharomyces cerevisiae. Mol Cell Biol 2004; 24: 10300 -12.
47. Wang X, Connelly JJ, Wang CL, Sternglanz R,. Importance of the Sir3 N terminus and its acetylation for yeast transcriptional silencing. Genetics 2004; 168: 547 -51.
48. Beliveau A, Yaswen P,. Soothing the watchman: telomerase reduces the p53-dependent cellular stress response. Cell Cycle 2007; 6: 1284 -7.
49. Yi CH, Sogah DK, Boyce M, Degterev A, Christofferson DE, Yuan J,. A genome-wide RNAi screen reveals multiple regulators of caspase activation. J Cell Biol 2007; 179: 619 -26.